Publications scientifiques en 2026

Depuis le 13/07/2026
  1. Impact of psychedelics on craving in addiction: A systematic review.
    Chapron SA, Bonazzi G, Di Lodovico L, de Ternay J, Landmann C, Nourredine M, Salvo F, Sessa B, Das R, Rolland B, Garcia-Romeu A, Auriacombe M.
    J Psychopharmacol. 2026
  2. Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With Human Immunodeficiency Virus Type 1: First Results From the ANRS-MIE CARLAPOP Study.
    Néant N, Lê MP, Bouchet S, Lagoutte-Renosi J, Grégoire M, Parant F, Venisse N, Lalanne S, Lemaitre F, Muret P, Renou Q, Destere A, Gandia P, Flandre P, Peytavin G, Solas C; ANRS-MIE-CARLAPOP Study Group.
    Clin Infect Dis. 2026
  3. Appropriateness of oxycodone use for acute pain in surgical and obstetric departments using a clinical data warehouse.
    Xuereb F, Trin K, Griffier R, Salvo F, Frasca M, Noize P, Bezin J, Pariente A.
    Br J Clin Pharmacol. 2026
  4. Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2.
    Lafay-Chebassier C, Girodet PO, Laine F, Allain JS, Pickering G, Latreille M, Demina A, Chevassus H, Ingrand I, Tartour E, Benhamouda N, Fraisse ML, Chamitava L, Plétan Y, Balland J, Donazzolo Y, Lafont B.
    Nicotine Tob Res. 2026
  5. The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine.
    Khouri C, Hlavaty A, Fusaroli M, Joshi N, Salvo F, Bate A, Pariente A, Raschi E.
    Clin Pharmacol Ther. 2026
  6. How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?
    Body C, Chassagnol F, Berdaï D, Bergmann JF, Borget I, Doré C, Durr A, Falissard B, Hudry J, Kowalski B, Maugendre P, Schlumberger N, Wilmet É, Le Jeunne C.
    Therapie. 2026
  7. Standardizing and Comparing Management Recommendations for Potential Drug-Drug Interactions Across Different Interaction Checkers.
    Crupi L, Letinier L, Jouhet V, Cossin S, Pariente A, Mathieu C, Martin GL, Konschelle F, Rouanet J, Carollo M, Trifirò G, Esposito E, Salvo F.
    Drug Saf. 2026
  8. How can the level of health product education (literacy) be raised among the general public?
    Locher C, Manaud N, Molimard M, Cassé-Perrot C, Cracowski JL, Di Palma C, Duchossoy L, Gatignol C, Goldgewicht A, Hertel O, Lacombe K, Lacroix C, Moreau-Chevrolet P, Quelet S, Rivière P, Lagouanelle MC, Micallef J.
    Therapie. 2026
  9. Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting system.
    Velişcu EM, Cagnotta C, Sullo MG, Anatriello A, Salvo F, Scavone C.
    Front Drug Saf Regul. 2026
  10. Drugs associated with generalized non-allergic pruritus: A World Health Organization pharmacovigilance database analysis.
    Kondor L, Cicala G, Salvo F, Clabecq C, Misery L, Brenaut E, Gourier G, Le Garrec R.
    J Am Acad Dermatol. 2026
  11. Coprescription of antipsychotics and benzodiazepines at hospital discharge.
    Demourgues M, Richaud A, Thiec J, Debruyne AL, Guillemin S, Tournier M, Salvo F, Queuille E.
    Encephale. 2026
  12. Language models in pharmacovigilance: Applications, promises and limits.
    Salvo F, Crupi L, Cholle C.
    Therapie. 2026
  13. Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle-Aquitaine.
    Munech-Herran M, Moysan V, Lescarret B, Mathieu C, Pariente A, Rousselot N.
    Br J Clin Pharmacol. 2026
  14. SGLT-2 Inhibitors Use in Hospitalized Patients in France: A Cross-Sectional Study.
    Demourgues M, Bezin J, Griffier R, Pariente A, Noize P, de Germay S.
    Fundam Clin Pharmacol. 2026
  15. PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies.
    Singier A, Bénard-Laribière A, Jarne-Munoz A, Pariente A, Veyrac G, Bezin J.
    Sci Rep. 2026
  16. Addictive disorders and correlates in the context of chemsex practices: A French online survey.
    Pavirani L, Jakubiec L, Daveluy A, Cazanave C, Desnavailles P, Fatseas M.
    Addict Behav Rep. 2026
  17. Drug prescription before and after dialysis initiation in older patients: a nationwide study.
    Faure L, Noize P, Couchoud C, Hucteau E, Berdougo J, Guerville F, Harambat J, Combe C, Levassort H, Moranne O, Hamroun A, Beuscart JB, Leffondré K, Prezelin-Reydit M; REIN registry.
    BMC Geriatr. 2026
  18. Sex Differences and Survival Among COPD Patients in France: The Palomb Cohort.
    Jestin-Guyon N, Ouaalaya EH, Bernady A, Berteaud E, Betancourt-Rial Z, Moinard J, Falque L, Le Guillou F, Molimard M, Nguyen L, Nocent C, Ozier A, Staali M, Raherison-Semjen C.
    Int J Chron Obstruct Pulmon Dis. 2026
  19. [Assessing the risk-benefit balance of medicines: Some lessons from Covid-19]
    Cracowski JL, Molimard M, Richard V, Roustit M, Khouri C.
    Med Sci (Paris). 2026
  20. Face à la désinformation en santé, l’inaction n’est pas une option.
    Maisonneuve H, Costagliola D, Molimard M.
    Rev Prat. 2026
  21. Comparison of the effect of donepezil and a combination of donepezil and mefloquine (THN201) on cognition during a scopolamine challenge in healthy participants.
    Dondaine T, Rein W, Micallef J, Cracowski JL, Girodet PO, Pickering G, Cracowski C, Thalamas C, Viardot G, L'Hostis P, Maurice D, Mouthon F, Charvériat M, Deplanque D, Bordet R.
    Exp Clin Psychopharmacol. 2026
  22. Serious respiratory distress associated with bosentan administration in chronic thromboembolic pulmonary hypertension: A case report.
    Perino J, Bassan P, Salvo F, Miremont-Salamé G, Maurac A, Dournes G, Girodet PO.
    Therapie. 2026
  23. Reply to "A Comment about AI Methods that May Help Advance Pharmacovigilance".
    Khouri C, Hlavaty A, Fusaroli M, Joshi N, Salvo F, Bate A, Pariente A, Raschi E.
    Clin Pharmacol Ther. 2026
  24. External Evaluation of Population Pharmacokinetic Models of Cabotegravir, During Its Oral and Intramuscular Administration in HIV-Infected Patients.
    Renou Q, Néant N, Destere A, Lagoutte-Renosi J, Grégoire M, Parant F, Lalanne S, Lemaitre F, Gandia P, Venisse N, Bouchet S, Lê MP, Muret P, Peytavin G, Solas C, Benaboud S; CARLA Study Group.
    CPT Pharmacometrics Syst Pharmacol. 2026
  25. [Accurate health information: A requirement for safety and social cohesion]
    Costagliola D, Maisonneuve H, Molimard M.
    Med Sci (Paris). 2026
  26. Opioid agonist treatment and risk of mortality in French primary care: a nationwide, retrospective cohort study.
    Dupouy J, Druel V, Verges Y, Pariente A, Lapeyre-Mestre M.
    Lancet Public Health. 2026
  27. Preliminary pharmacokinetic investigation of two discoidin domain receptor 2 inhibitors in murine plasma and brain using liquid chromatography-tandem mass spectrometry analysis.
    Gueroue P, Burban A, Sharanek A, Bougueon G, Bouchet S, Ducint D, Molimard M, Djabarouti S, Guyon J.
    Sci Rep. 2026